A Phase Ib Study With Pegylated Recombinant Human Endostatin in Advanced / Metastatic NSCLC or Other Solid Tumors
Status:
Recruiting
Trial end date:
2021-09-30
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to examine the safety, tolerability and pharmacokinetics
of PEG-ENDO in combination with docetaxel in subjects previously treated or untreated
(standard therapy is not suitable or without standard therapy) for advanced or metatatic
non-small cell lung cancer (NSCLC) or other solid tumors.